Clinical Trials – Cancer Care - VA Portland Health Care System
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

VA Portland Health Care System

Veterans Crisis Line Badge
My HealtheVet badge

Clinical Trials – Cancer Care

VA Portland Health Care System participates in cancer research to bring the latest advances in diagnostic testing and procedures, surgery, medicine, radiation therapy, and supportive care to our Veterans.  We have national experts as well as work with Oregon Health & Science University (OHSU) and national research organizations to offer Veterans cutting edge care and learn more about the best ways to diagnose and treat cancer. 

We offer Veterans with cancer the opportunity to participate in clinical trials.  If you are interested in learning more about clinical trials available at VA Portland, please speak with your doctor.


The NCI and VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE) program is a partnership between the National Cancer Institute (NCI) and the Department of Veterans Affairs (VA) to facilitate enrollment of Veterans with cancer into NCI-funded clinical trials.  This provides more access to the latest treatment options for VA patients with cancer.  Portland VA Medical Center is one of 12 centers across the US selected to launch this program.  The principal investigator is Mark Garzotto, MD.   

Cancer Clinical Trials at VA Portland

Find cancer clinical trials available at VA Portland in the list below.  For more information about VA Portland clinical trials that you may be eligible for, please speak with your doctor.  

Hematologic Cancers

Principal Investigator Title Trial Details 
Derek Galligan, MD The National Myelodysplastic Syndromes (MDS) Study (MDS) NCT02775383


Principal Investigator Title Trial Details 
Rajan Kulkarni, MD A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for
High-Risk Melanoma



Prostate Cancer

Principal Investigator Title Trial Details 
Graff, MD
Fecal Microbiota Transplant and Pembrolizumab for Men with Metastatic Castration Resistant Prostate Cancer NCT04116775
Mark Garzotto, MD Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer NCT03753243
Mark Garzotto, MD Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03) NCT01436968
Graff, MD
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) NCT02975934

Urologic / Genitourinary Cancers

Principal Investigator Title Trial Details (link)
Ryan Kopp, MD Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866) NCT03924856

More Information about Clinical Trials

Page updated January 29, 2021